Street Calls of the Week
Amneal Pharmaceuticals Inc Class A stock reached a new 52-week high, closing at $10.36, with analysts setting price targets as high as $14. According to InvestingPro analysis, the stock appears slightly overvalued at current levels. This milestone marks a significant point for the company, reflecting a positive trajectory over the past year. With a market capitalization of $3.24 billion, Amneal Pharmaceuticals has delivered impressive returns, posting a year-to-date gain of 26.39% and revenue growth of 9.81%. The company’s stock has been on an upward trend, capturing attention as it continues to navigate the competitive pharmaceutical landscape. InvestingPro subscribers can access 8 additional key insights about AMRX’s financial health and growth prospects.
In other recent news, Amneal Pharmaceuticals reported its second-quarter 2025 earnings, with earnings per share (EPS) exceeding analysts’ expectations. The company achieved an EPS of $0.25, surpassing the anticipated $0.17. However, revenue fell slightly short of projections, reaching $725 million compared to the expected $748.18 million. In regulatory developments, Amneal submitted a Biologics License Application to the U.S. Food and Drug Administration for a biosimilar to Xolair, developed by Kashiv BioSciences. Additionally, the FDA approved Amneal’s generic version of bimatoprost for treating glaucoma, as well as its generic risperidone for schizophrenia treatment. These approvals mark significant advancements for Amneal in the generic drug market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.